Form 4 for IT Gartner
Accepted 2025-02-18 00:00:00 ET · period of report 2025-02-13 · accession 0001127602-25-005288 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-02-18 | 2025-02-13 | IT | Genovese Yvonne | EVP, Gbl Product Management | F - Tax | $517.17 | -1,400 | 6,629 | -17% | -$724.0K |
| D | 2025-02-18 | 2025-02-13 | IT | Genovese Yvonne | EVP, Gbl Product Management | M - OptEx | $180.64 | +4,826 | 9,715 | +99% | +$871.8K |
| D | 2025-02-18 | 2025-02-13 | IT | Genovese Yvonne | EVP, Gbl Product Management | D - Sale to Iss | $517.17 | -1,686 | 8,029 | -17% | -$871.9K |
| D | 2025-02-18 | 2025-02-13 | IT | Genovese Yvonne | EVP, Gbl Product Management | M - OptEx | $0.00 | -4,826 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-02-13 | F | D | 1,400 | $517.17 | 6,629 | D | — | — | (F3) Represents shares withheld for the payment of applicable income and payroll withholding taxes. |
| 2 | Common | Common Stock | 2025-02-13 | M | A | 4,826 | $180.64 | 9,715 | D | — | — | (F1) Represents shares acquired upon exercise of SARs. |
| 3 | Common | Common Stock | 2025-02-13 | D | D | 1,686 | $517.17 | 8,029 | D | — | — | (F2) Represents shares withheld that had an aggregate value, based on the market price on the date of exercise, substantially equal to the aggregate exercise price of the SARs. |
| 4 | Derivative | Stock Appreciation Rights | 2025-02-13 | M | D | 4,826 | $0.00 | 0 | D | $180.64 · 2022-02-10 to 2028-02-10 | 4,826 Common Stock | (F4) These SARs are part of an award that became exercisable in four substantially equal annual installments, commencing on February 10, 2022, and are fully exercisable. |